INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...
Remibrutinib results in significant improvement in patients still symptomatic after second-generation H1-antihistamine treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback